Highlights & Basics
- Erectile dysfunction (ED) increases with age and some degree of erectile difficulty is reported by half of men ages 40 to 70 years. Screening should take place as part of routine health assessment.
- May be associated with established cardiovascular risk factors or be a precursor to significant cardiovascular, psychological, or endocrine disease.
- ED-specific therapy may involve pharmacotherapy, external devices, and surgical therapy. Psychosocial interventions, such as individual and/or couples psychotherapy, may improve erectile function.
- Oral phosphodiesterase-5 inhibitors are the primary pharmacotherapy used for ED.
- Patients with a complex underlying cause, and those with inadequate response to treatment who request continued therapy, should be evaluated by a urologist.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Citations
Dewitte M, Bettocchi C, Carvalho J, et al. A psychosocial approach to erectile dysfunction: position statements from the European Society of Sexual Medicine (ESSM). Sex Med. 2021 Dec;9(6):100434.[Abstract][Full Text]
Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018 Sep;200(3):633-41.[Abstract][Full Text]
Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012 Aug;87(8):766-78.[Abstract][Full Text]
Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999 Dec;11(6):319-26.[Abstract]
1. McCabe MP, Sharlip ID, Atalla E, et al. Definitions of sexual dysfunctions in women and men: a consensus statement from the fourth international consultation on sexual medicine 2015. J Sex Med. 2016 Feb;13(2):135-43.[Abstract]
2. National Institutes of Health. Impotence: NIH consensus development panel on impotence. JAMA. 1993 Jul 7;270(1):83-90.[Abstract]
3. Lizza EF, Rosen RC. Definition and classification of erectile dysfunction: report of the nomenclature committee of the International Society of Impotence Research. Int J Impot Res. 1999 Jun;11(3):141-3.[Abstract]
4. Auld RB, Brock G. Sexuality and erectile dysfunction: results of a national survey. J Sex Reprod Med 2002;2(2):50-4.[Full Text]
5. Kessler A, Sollie S, Challacombe B, et al. The global prevalence of erectile dysfunction: a review. BJU Int. 2019 Oct;124(4):587-99.[Abstract]
6. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61.[Abstract]
7. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000 Feb;163(2):460-3.[Abstract]
8. Capogrosso P, Colicchia M, Ventimiglia E, et al. One patient out of four with newly diagnosed erectile dysfunction is a young man--worrisome picture from the everyday clinical practice. J Sex Med. 2013 Jul;10(7):1833-41.[Abstract]
9. Calzo JP, Austin SB, Charlton BM, et al. Erectile dysfunction in a sample of sexually active young adult men from a U.S. cohort: demographic, metabolic and mental health correlates. J Urol. 2021 Feb;205(2):539-44.[Abstract]
10. Saigal CS, Wessells H, Pace J, et al. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med. 2006 Jan 23;166(2):207-12.[Abstract][Full Text]
11. Kupelian V, Link CL, Rosen RC, et al. Socioeconomic status, not race/ethnicity, contributes to variation in the prevalence of erectile dysfunction: results from the Boston Area Community Health (BACH) Survey. J Sex Med. 2008 Jun;5(6):1325-33.[Abstract]
12. Yafi FA, Jenkins L, Albersen M, et al. Erectile dysfunction. Nat Rev Dis Primers. 2016 Feb 4;2:16003.[Abstract][Full Text]
13. Dewitte M, Bettocchi C, Carvalho J, et al. A psychosocial approach to erectile dysfunction: position statements from the European Society of Sexual Medicine (ESSM). Sex Med. 2021 Dec;9(6):100434.[Abstract][Full Text]
14. Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013 Jan 12;381(9861):153-65.[Abstract]
15. Goldstein I. Male sexual circuitry. Sci Am. 2000 Aug;283(2):70-5.
16. Cignarelli A, Genchi VA, D'Oria R, et al. Role of glucose-lowering medications in erectile dysfunction. J Clin Med. 2021 Jun 5;10(11):2501.[Abstract][Full Text]
17. Salvio G, Martino M, Giancola G, et al. Hypothalamic-pituitary diseases and erectile dysfunction. J Clin Med. 2021 Jun 9;10(12):2551.[Abstract][Full Text]
18. Guay AT, Spark RF, Bansal S, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update. Endocr Pract. 2003 Jan-Feb;9(1):77-95.[Abstract]
19. National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management. Dec 2021 [internet publication].[Full Text]
20. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am. 2005 Nov;32(4):379-95, v.[Abstract][Full Text]
21. McCabe MP, Althof SE. A systematic review of the psychosocial outcomes associated with erectile dysfunction: does the impact of erectile dysfunction extend beyond a man's inability to have sex? J Sex Med. 2014 Feb;11(2):347-63.[Abstract]
22. Li S, Song JM, Zhang K, et al. A meta-analysis of erectile dysfunction and alcohol consumption. Urol Int. 2021;105(11-12):969-85.[Abstract]
23. Reffelmann T, Kloner RA. Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag. 2006;2(4):447-55.[Abstract][Full Text]
24. Burchardt M, Burchardt T, Baer L, et al. Hypertension is associated with severe erectile dysfunction. J Urol. 2000 Oct;164(4):1188-91.[Abstract]
25. Maas R, Schwedhelm E, Albsmeier J, et al. The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med. 2002 Aug;7(3):213-25.[Abstract]
26. Tóth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006. J Clin Lipidol. 2012 Jul-Aug;6(4):325-30.[Abstract][Full Text]
27. Kim SC. Hyperlipidemia and erectile dysfunction. Asian J Androl. 2000 Sep;2(3):161-6.[Abstract]
28. Kouidrat Y, Pizzol D, Cosco T, et al. High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies. Diabet Med. 2017 Sep;34(9):1185-92.[Abstract]
29. De Berardis G, Pellegrini F, Franciosi M, et al; Quality of Care and Outcomes in Type 2 Diabetes Study Group. Identifying patients with type 2 diabetes with a higher likelihood of erectile dysfunction: the role of the interaction between clinical and psychological factors. J Urol. 2003 Apr;169(4):1422-8.[Abstract]
30. Stehouwer CD, Lamber J, Konker AJ, et al. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res. 1997 Apr;34(1):55-68.[Abstract]
31. Pizzol D, Smith L, Fontana L, et al. Associations between body mass index, waist circumference and erectile dysfunction: a systematic review and META-analysis. Rev Endocr Metab Disord. 2020 Dec;21(4):657-66.[Abstract][Full Text]
32. Corona G, Rastrelli G, Filippi S, et al. Erectile dysfunction and central obesity: an Italian perspective. Asian J Androl. 2014 Jul-Aug;16(4):581-91.[Abstract][Full Text]
33. Feldman HA, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med. 2000 Apr;30(4):328-38.[Abstract]
34. Kovac JR, Labbate C, Ramasamy R, et al. Effects of cigarette smoking on erectile dysfunction. Andrologia. 2015 Dec;47(10):1087-92.[Abstract][Full Text]
35. Burnett AL. Metabolic syndrome, endothelial dysfunction, and erectile dysfunction: association and management. Curr Urol Rep. 2005 Nov;6(6):470-5.[Abstract]
36. Demir T, Demir O, Kefi A, et al. Prevalence of erectile dysfunction in patients with metabolic syndrome. Int J Urol. 2006 Apr;13(4):385-8.[Abstract]
37. Shridharani AN, Brant WO. The treatment of erectile dysfunction in patients with neurogenic disease. Transl Androl Urol. 2016 Feb;5(1):88-101.[Abstract][Full Text]
38. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. 1982 Sep;128(3):492-7.[Abstract]
39. Yeager ES, Van Heerden JA. Sexual dysfunction following proctocolectomy and abdominoperineal resection. Ann Surg. 1980 Feb;191(2):169-70.[Abstract][Full Text]
40. Padma-Nathan H, McCullough A, Forest C. Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. Curr Urol Rep. 2004 Dec;5(6):467-71.[Abstract]
41. Wright JL, Nathens AB, Rivara FP, et al. Specific fracture configurations predict sexual and excretory dysfunction in men and women 1 year after pelvic fracture. J Urol. 2006 Oct;176(4 Pt 1):1540-5; discussion 1545.[Abstract]
42. Nehra A, Alterowitz R, Culkin DJ, et al; American Urological Association. Peyronie's disease: AUA guideline. J Urol. 2015 Sep;194(3):745-53.[Abstract][Full Text]
43. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999 Feb;19(1):67-85.[Abstract]
44. Shindel AW, Althof SE, Carrier S, et al. Disorders of ejaculation: an AUA/SMSNA guideline. J Urol. 2022 Mar;207(3):504-12.[Abstract][Full Text]
45. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018 May 1;103(5):1715-44.[Abstract][Full Text]
46. Ricchiuti VS, Haas CA, Seftel AD, et al. Pudendal nerve injury associated with avid bicycling. J Urol. 1999 Dec;162(6):2099-100.[Abstract]
47. Egerdie RB, Auerbach S, Roehrborn CG, et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med. 2012 Jan;9(1):271-81.[Abstract]
48. Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018 Sep;200(3):633-41.[Abstract][Full Text]
49. Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012 Aug;87(8):766-78.[Abstract][Full Text]
50. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997 Jun;49(6):822-30.[Abstract]
51. Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999 Dec;11(6):319-26.[Abstract]
52. Moreland RB, Nehra A. Pathophysiology of Peyronie's disease. Int J Impot Res. 2002 Oct;14(5):406-10.[Abstract]
53. Ciocanel O, Power K, Eriksen A. Interventions to treat erectile dysfunction and premature ejaculation: an overview of systematic reviews. Sex Med. 2019 Sep;7(3):251-69.[Abstract][Full Text]
54. Gholami SS, Gonzalez-Cadavid NF, Lin CS, et al. Peyronie's disease: a review. J Urol. 2003 Apr;169(4):1234-41.[Abstract]
55. Practice Committee of the American Society for Reproductive Medicine in Collaboration with the Society for Male Reproduction and Urology. Electronic address: asrm@asrm.org. Diagnostic evaluation of sexual dysfunction in the male partner in the setting of infertility: a committee opinion. Fertil Steril. 2023 Nov;120(5):967-72.[Abstract][Full Text]
56. Capogrosso P, Jensen CFS, Rastrelli G, et al. Male sexual dysfunctions in the infertile couple-recommendations from the European Society of Sexual Medicine (ESSM). Sex Med. 2021 Jun;9(3):100377.[Abstract][Full Text]
57. Lue TF, Giuliano F, Montorsi F, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2004 Jul;1(1):6-23.[Abstract]
58. Spratt DI, Bigos ST, Beitins I, et al. Both hyper- and hypogonadotrophic hypogonadism occur transiently in acute illness: bio- and immunoactive gonadotropins. J Clin Endocrinol Metab. 1992 Dec;75(6):1562-70.[Abstract]
59. Baskin HJ, Cobin RH, Duick DS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002 Nov-Dec;8(6):457-69.[Abstract]
60. Bivalacqua TJ, Allen BK, Brock G, et al. Acute ischemic priapism: an AUA/SMSNA guideline. J Urol. 2021 Nov;206(5):1114-21.[Abstract][Full Text]
61. Bivalacqua TJ, Allen BK, Brock GB, et al. The diagnosis and management of recurrent ischemic priapism, priapism in sickle sell patients, and non-ischemic priapism: an AUA/SMSNA guideline. J Urol. 2022 Jul;208(1):43-52.[Abstract][Full Text]
62. Rosen RC, Cappelleri JC, Gendrano N 3rd. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res. 2002 Aug;14(4):226-44.[Abstract][Full Text]
63. Cappelleri JC, Rosen RC, Smith MD, et al. Diagnostic evaluation of the erectile function domain of the international index of erectile function. Urology. 1999 Aug;54(2):346-51.[Abstract]
64. Domes T, Najafabadi BT, Roberts M, et al. Canadian Urological Association guideline: erectile dysfunction. Can Urol Assoc J. 2021 Oct;15(10):310-22.[Abstract][Full Text]
65. Bella AJ, Lee JC, Grober ED, et al. 2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature. Can Urol Assoc J. 2018 Feb 22;12(5):E197-209.[Abstract][Full Text]
66. European Association of Urology. Sexual and reproductive health. 2022 [internet publication].[Full Text]
67. Wing RR, Rosen RC, Fava JL, et al. Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med. 2010 Jan;7(1 Pt 1):156-65.[Abstract]
68. Gupta BP, Murad MH, Clifton MM, et al. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2011 Nov 14;171(20):1797-803.[Abstract][Full Text]
69. Salonia A, Adaikan G, Buvat J, et al. Sexual rehabilitation after treatment for prostate cancer-part 2: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2017 Mar;14(3):297-315.[Abstract][Full Text]
70. Hatzimouratidis K, Salonia A, Adaikan G, et al. Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016 Mar 25;13(4):465-88.[Abstract]
71. Pyrgidis N, Mykoniatis I, Haidich AB, et al. The effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews. Front Pharmacol. 2021;12:735708.[Abstract][Full Text]
72. Yafi FA, Sharlip ID, Becher EF. Update on the safety of phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. Sex Med Rev. 2018 Apr;6(2):242-52.[Abstract]
73. Azzouni F, Abu Samra K. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. J Sex Med. 2011 Oct;8(10):2894-903.[Abstract]
74. Zhou Z, Chen H, Wu J, et al. Meta-analysis of the long-term efficacy and tolerance of tadalafil daily compared with tadalafil on-demand in treating men with erectile dysfunction. Sex Med. 2019 Sep;7(3):282-91.[Abstract][Full Text]
75. Kim E, Seftel A, Goldfischer E, et al. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil. Curr Med Res Opin. 2014 Dec 2;31(2):379-89.[Abstract]
76. Loeb S, Folkvaljon Y, Lambe M, et al. Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA. 2015 Jun 23-30;313(24):2449-55. [Abstract][Full Text]
77. Jenkins LC, Hall M, Deveci S, et al. An evaluation of a clinical care pathway for the management of men with nonorganic erectile dysfunction. J Sex Med. 2019 Oct;16(10):1541-6.[Abstract][Full Text]
78. Khera M, Goldstein I. Erectile dysfunction. BMJ Clin Evid. 2011 Jun 29;2011. pii: 1803.[Abstract][Full Text]
79. Costa P, Potempa AJ. Intraurethral alprostadil for erectile dysfunction: a review of the literature. Drugs. 2012 Dec 3;72(17):2243-54.[Abstract]
80. Anaissie J, Hellstrom WJ. Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review. Res Rep Urol. 2016;8:123-31.[Abstract][Full Text]
81. Babaei AR, Safarinejad MR, Kolahi AA, et al. Penile revascularization for erectile dysfunction: a systematic review and meta-analysis of effectiveness and complications. Urol J. 2009 Winter;6(1):1-7.[Abstract][Full Text]
82. Kim ED, Owen RC, White GS, et al. Endovascular treatment of vasculogenic erectile dysfunction. Asian J Androl. 2015 Jan-Feb;17(1):40-3.[Abstract][Full Text]
83. Melnik T, Soares BG, Nasselo AG. Psychosocial interventions for erectile dysfunction. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD004825.[Abstract][Full Text]
84. Montorsi F, Adaikan G, Becher E, et al. Committee 26. Summary of the recommendations on sexual dysfunctions in men. In: Montorsi F, Basson R, Adaikan G, eds. Sexual medicine: sexual dysfunctions in men and women. Edition 2010. Paris: Editions 21; 2010:1265-82.[Abstract][Full Text]
85. Pyrgidis N, Mykoniatis I, Haidich AB, et al. Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses. BMJ Open. 2021 Aug 24;11(8):e047396.[Abstract][Full Text]
86. Hellstrom WJ, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl. 2002 Nov-Dec;23(6):763-71.[Abstract][Full Text]
87. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al; Medicated Urethral System for Erection (MUSE) Study Group. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med. 1997 Jan 2;336(1):1-7.[Abstract]
88. Cookson MS, Nadig PW. Long-term results with vacuum constriction device. J Urol. 1993 Feb;149(2):290-4. [Abstract]
89. Mulcahy JJ. Current approach to the treatment of penile implant infections. Ther Adv Urol. 2010 Apr;2(2):69-75.[Abstract][Full Text]
90. Bella AJ, Deyoung LX, Al-Numi M, et al. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur Urol. 2007 Oct;52(4):990-1005.[Abstract]
91. Liu JL, Chu KY, Gabrielson AT, et al. Restorative therapies for erectile dysfunction: position statement from the Sexual Medicine Society of North America (SMSNA). Sex Med. 2021 Jun;9(3):100343.[Abstract][Full Text]
92. Raheem OA, Natale C, Dick B, et al. Novel treatments of erectile dysfunction: review of the current literature. Sex Med Rev. 2021 Jan;9(1):123-32.[Abstract]
93. Yao H, Wang X, Liu H, et al. Systematic review and meta-analysis of 16 randomized controlled trials of clinical outcomes of low-intensity extracorporeal shock wave therapy in treating erectile dysfunction. Am J Mens Health. 2022 Mar-Apr;16(2):15579883221087532.[Abstract][Full Text]
94. Montorsi F, Brock G, Stolzenburg JU, et al. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT). Eur Urol. 2014 Mar;65(3):587-96.[Abstract]
95. Philippou YA, Jung JH, Steggall MJ, et al. Penile rehabilitation for postprostatectomy erectile dysfunction. Cochrane Database Syst Rev. 2018 Oct 23;(10):CD012414.[Abstract][Full Text]
96. Pisansky TM, Pugh SL, Greenberg RE, et al. Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial. JAMA. 2014 Apr 2;311(13):1300-7.[Abstract]
97. Mulhall JP, Brock G, Oelke M, et al. Effects of tadalafil once-daily or on-demand vs placebo on return to baseline erectile function after bilateral nerve-sparing radical prostatectomy--results from a randomized controlled trial (REACTT). J Sex Med. 2016 Apr;13(4):679-83.[Abstract][Full Text]
98. King SH, Mayorov AV, Balse-Srinivasan P, et al. Melanocortin receptors, melanotropic peptides and penile erection. Curr Top Med Chem. 2007;7(11):1098-106.[Abstract]
99. Rosen RC, Diamond LE, Earle DC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to viagra. Int J Impot Res. 2004 Apr;16(2):135-42.[Abstract]
100. Safarinejad MR, Hosseini SY. Expression of concern: salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2023 Jan 10;:101097JU0000000000003117.[Abstract]
101. Kim S, Cho MC, Cho SY, et al. Novel emerging therapies for erectile dysfunction. World J Mens Health. 2021 Jan;39(1):48-64.[Abstract][Full Text]
102. Diamond LE, Earle DC, Garcia WD, et al. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005 Apr;65(4):755-9.[Abstract]
103. Yoshimura N, Kato R, Chancellor MB, et al. Gene therapy as future treatment of erectile dysfunction. Expert Opin Biol Ther. 2010 Sep;10(9):1305-14.[Abstract][Full Text]
104. Lai BY, Cao HJ, Yang GY, et al. Acupuncture for treatment of erectile dysfunction: a systematic review and meta-analysis. World J Mens Health. 2019 Sep;37(3):322-38.[Abstract][Full Text]
105. McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ. 2006 Mar 11;332(7541):589-92.[Abstract][Full Text]
106. Madeira CR, Tonin FS, Fachi MM, et al. Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis. World J Urol. 2021 Mar;39(3):953-62.[Abstract]
107. Zhu J, Zhang W, Ou N, et al. Do testosterone supplements enhance response to phosphodiesterase 5 inhibitors in men with erectile dysfunction and hypogonadism: a systematic review and meta-analysis. Transl Androl Urol. 2020 Apr;9(2):591-600.[Abstract][Full Text]
108. Defeudis G, Mazzilli R, Tenuta M, et al. Erectile dysfunction and diabetes: a melting pot of circumstances and treatments. Diabetes Metab Res Rev. 2022 Feb;38(2):e3494.[Abstract][Full Text]
109. Guay AT, Perez JB, Jacobson J, et al. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl. 2001 Sep-Oct;22(5):793-7.[Abstract]
110. Williams G, Abbou CC, Amar ET, et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. Br J Urol. 1998 Jun;81(6):889-94.[Abstract]
111. Hatzichristou DG, Pescatori ES. Current treatments and emerging therapeutic approaches in male erectile dysfunction. BJU Int. 2001;88(suppl 3):11-17.[Abstract]
112. Danesh-Meyer HV, Levin LA. Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association? Br J Ophthalmol. 2007 Nov;91(11):1551-5.[Abstract]
113. Laties AM. Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. Drug Saf. 2009;32(1):1-18.[Abstract]
114. Ostfeld RJ, Allen KE, Aspry K, et al. Vasculogenic erectile dysfunction: the impact of diet and lifestyle. Am J Med. 2021 Mar;134(3):310-6.[Abstract]
115. Begot I, Peixoto TC, Gonzaga LR, et al. A home-based walking program improves erectile dysfunction in men with an acute myocardial infarction. Am J Cardiol. 2015 Mar 1;115(5):571-5.[Abstract]
